MTOR and hepatocellular carcinoma: Briefly, JMJD2D promotes the transcription of various oncogenes by cooperating with β-catenin, Gli1/2, HIF1α, TCF4, and NICD, and then activates matched carcinogenic pathways, including Wnt/β-catenin, Hedgehog, mTOR-HIF1α, β-catenin/TCF4, and Notch signaling pathways that drive CRC or HCC progression.